|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 16, 2012 ) New York, NY -- Titan Pharmaceuticals (TTNP) and Advanced Cell Technology (ACTC) are looking to bring their respective unique technologies to market, as identified by VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors.
Shares of Titan Pharmaceuticals TTNP had been trading with increased volume all month long thus far, and late last week that volume boost solidified into share price gains, too. Titan's stock opened the month of July trading at sixty five cents, but barely two weeks later shares closed last week at seventy nine cents, a significant percentage increase for those that took advantage of the dip.
With volume still trading significantly above the recognized average for the weeks leading into the most recent boost, TTNP shares are threatening to continue their move higher.
News hit the wires last week that Titan is developing a pipeline beyond just Probuphine for opioid addiction and chronic pain, having announced that the company had completed pre-clinical work on a product that puts ProNeura to work against Parkinson's, but it's unlikely that such news related to a pre-clinical product would have the volume and price impact TTNP shares that has been seen over the past few weeks.
With that being the case, it's time to speculate as to what likely could be behind the move. Investors may be taking positions in preparation for the anticipated approval filing with the FDA for Probuphine in the treatment of opioid addiction, an event that is expected to take place in or around September of this year.
For full report on Titan visit: http://vfcsstockhouse.com/blog/article/-titan-pharmaceuticals-ttnp-shares-inching-higher
Still - and again - trading for under ten cents, it's worth keeping shares of Advanced Cell Technology (ACTC) on the radar. The trading history of this stock has demonstrated to us that buys below the dime level eventually turn into decent trades, while still holding the potential to materialize into long term gains, too, as the clinical trials develop.
Discounted as just another "penny stock" to many, ACT was launched into the spotlight a while back when the FDA made the relatively tiny company only the second to receive an approval to conduct trials based on stem cell research. Geron (GERN) had been the first, but that company has since put its stem cell treatment for spinal cord injuries on hold in order to concentrate resources towards other pipeline candidates, which makes Advanced Cell the arguable leader in a potentially revolutionary medical field.
For full report on ACT visit: http://vfcsstockhouse.com/blog/article/-advanced-cell-technology-actc-a-transformational-game-changer
For this week's list of hot stocks to watch visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-16-july-ko-jnj-goog-tlle-imsc-ssh-amrn-ttnp-actc-mric-vz-yum-amzn-appl-fb-cmcsa-yhoo-msft-rimm-gs-ms-bsx-si-sppi-pbth-mrk-vvus-ko-celh-ge-cpst-jpm-wfc-bac-c-ubs-rbs-db-usb-
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, growth stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
